Effects of recombinant bovine somatotropin on nutritional status and liver function of lactating dairy cows

Twenty-four high producing, multiparous Holstein cows were utilized to evaluate effects of long-term administration of sustained-release rbST on blood pH, gases, buffer capacity, circulating metabolites and hormones, and on liver lipid content and functions during lactation. Treatment, commencing 98 to 112 d postpartum and continued until d 305, consisted of a subcutaneous injection of a placebo or 350 mg of rbST every 14 d. Milk and 3.5% FCM were increased significantly by rbST, but milk fat and protein content, feed intake, energy balance, corrected feed efficiency for milk production, and body condition scores were unaffected. Somatotropin decreased blood pH and buffer capacity by decreasing bicarbonate without affecting blood partial pressures of oxygen or carbon dioxide. Concentration of plasma albumin was decreased and nonesterified fatty acids, glucose, insulin, rbST and insulin-like growth factor-I were increased by treatment. Total plasma proteins and cortisol, hemoglobin, and hematocrit were unaffected. Liver DM, total lipid and triacylglycerol contents, and plasma 3-hydroxybutyrate and glutamic oxalacetic transaminase were not affected by rbST, but the percentage of triacylglycerol in total lipids was increased. Results of this experiment suggest that rbST exhibited lipolytic and diabetogenic activities in lactating dairy cows in vivo and that these effects might be important for the increase in nutrient partitioning toward the mammary gland elicited by rbST.     

Fertility of lactating dairy cows administered recombinant bovine somatotropin during heat stress

Administration of recombinant bovine somatotropin (bST) to lactating dairy cows during heat stress increases milk yield, but it also can increase body temperature and may therefore compromise fertility. However, it is possible that bST treatment could increase fertility during heat stress because it has been reported to increase fertility in lactating cows. In addition, bST increases secretion of insulin-like growth factor-I (IGF-I) that promotes embryo survival. The purpose of this study was to determine effects of bST on reproductive function in lactating dairy cows during heat stress. The experiment was conducted in southern Georgia from July to November 2005 using lactating Holstein cows (n = 276 for reproductive traits). For first service timed artificial insemination (TAI), cows were presynchronized with 2 injections of PGF_2α given 14 d apart followed by a modified Ovsynch protocol (GnRH and insemination at 72 h following PGF_2α). Pregnancy was diagnosed by using ultrasonography on d 29 and reconfirmed by palpation between d 45 and 80 post-TAI. Nonpregnant cows were resynchronized with the modified Ovsynch protocol and received a second TAI. Treatment with bST started 1 wk before the start of Ovsynch and continued at 2-wk intervals. Blood samples were collected from a subset of cows to determine IGF-I profiles immediately before the first bST injection, 1 wk later, and at d 35 of bST treatment. Rectal temperatures were assessed on d 29 of bST treatment. Pregnancy rates (d 45 to 80 post-TAI) did not differ between bST and control cows for first- (16.7 vs. 15.2%) or second-service TAI (14.8 vs. 17.2%). Plasma concentrations of IGF-I and milk yield were greater for bST-treated cows following the initiation of bST treatment and bST increased rectal and vaginal temperatures. Body condition score was less for bST-treated cows. In conclusion, treatment with bST during heat stress increased IGF-I concentrations, milk yield over time, and rectal and vaginal temperatures without affecting first- or second-service pregnancy rates. Thus, at least under certain housing conditions, bST can be used to improve milk yield during heat stress without compromising fertility.     

Relationship of thermal status to productivity in heat-stressed dairy cows given recombinant bovine somatotropin

The responses of lactating Holstein cows to daily administration of bovine somatotropin (bST) were measured at thermoneutrality (Tn) and under both constant and cycled heat-stress conditions to determine the relationship between thermal status and bST-induced shifts in milk production. All tests included a 5-d acclimation period at Tn (18°C), followed by a 2-d increase in ambient temperature to 28.5°C. After d 3, ambient temperature was cycled between 28.5 (day) and 25.5°C (night) for 4 d. Daily injections with either 31 mg of bST or saline began on d 1 of the experiment. Milk production, feed intake, and respiratory rate (RR) were measured daily. Intraperitoneal, telemetric temperature transmitters were used for a continuous measure of core body temperature (T_core). Blood samples were collected during each phase to evaluate the changes in serum chemistry in response to bST and heat stress. Following a 15-d recovery, cows were switched across injection treatments and the study was repeated. Milk production decreased by ∼18.4% below the initial yield at Tn by the end of 7 d of heat challenge. Although a reduction in milk production occurred during heat stress in both groups, milk production was higher in bST-treated cows compared with control cows during periods of constant and cyclic heat. Likewise, bST treatment during the entire period increased the milk-to-feed ratio over the control level by ∼11.3%. Plasma insulin-like growth factor 1 and serum nonesterified fatty acids accompanied the increased growth hormone level with bST treatment (∼122.0 and 88.8%, respectively), whereas plasma urea nitrogen was reduced by ∼13.3% to reflect the shift to lipid metabolism. There was no difference in T_core of the treatment and control groups at Tn. Both bST and control cows increased RR and T_core above the Tn level by ∼94.8 and 2.9%, respectively, during constant heat, with a greater increase in T_core of bST-treated compared with control cows (∼0.6%). The increase in RR during heat stress preceded T_core by 1 d for both groups. During cyclic heat, T_core decreased by ∼0.4% compared with constant heat in both the control and bST-treated groups. Bovine somatotropin treatment increased milk production similarly during the Tn and heat-stress periods, ∼8.3% over the control; however, the bST-induced increase in milk-to-feed ratio was greatest during the continuous and cyclic heat-stress phases, ∼16.2%. This increase occurred together with the elevation in T_core.     

Effects of whole cottonseed diet and recombinant bovine somatotropin on ovarian follicles in lactating dairy cows

The effects of whole cottonseed (WCS) in the diet and the administration of bovine somatotropin (bST) on ovarian follicular dynamics and plasma progesterone (P4) concentrations were examined in cows during a period of synchronized follicular growth. Lactating Holstein cows (n = 28) were randomly assigned to treatments in a 2 x 2 factorial arrangement. Diets consisted of WCS (15% of dry matter) or no WCS, and bST at a dose of 0 or 208 mg/14 d. Dietary treatments began within 24 h of calving and bST treatments began within 7 d postpartum. Cows received GnRH at 65 +/- 3 d postpartum (d 0), PGF2alpha, (d 7), a second dose of GnRH (d 9), and were inseminated 16 h later (d 10). Ovarian changes were monitored daily by ultrasonography from d 0 to 9. On d 9,93% of cows had a preovulatory follicle and 86% ovulated. For Class 2 (6 to 9 mm) follicles, a diet x bST interaction was detected, with bST stimulating Class 2 follicles in cows fed WCS, but not in cows on the control diet. Neither diet nor bST affected numbers of Class 1 (2 to 5 mm) or Class 3 (> or = 10 mm) follicles or sizes of the subordinate and dominant follicles. During the luteal phase of the cycle, lactating cows fed WCS tended to have elevated concentrations of plasma P4, whereas bST was without effect. Plasma concentrations of high-density lipoprotein cholesterol were increased in cows fed WCS. Number and diameter of corpora lutea did not differ among treatments.     

Effects of treatment of preweaning dairy calves with recombinant bovine somatotropin on immune responses and somatotropic axis

Weaning may be associated with negative energy balance and body weight loss when calves are still immunologically immature, predisposing them to infectious diseases. The aim of the present experiment was to investigate the effects of treatment of preweaning dairy calves with recombinant bovine somatotropin (rbST) on the somatotropic axis, selected immune parameters, and hematology of calves around weaning. Thirty-six Holstein female calves were randomly assigned to receive 1.5 to 1.8 mg of rbST (Posilac, Elanco Animal Health, Greenfield, IN) per kilogram of body weight or to receive injections of saline (saline solution 0.9%, Valley Vet Supply, Marysville, KS) every 7 d from 21 to 63 d of life. Calves were fed milk replacer ad libitum from birth to 38 d of age (d ?11), when progressive weaning started, and calves were weaned at 49 d of age (d 0). Calves were weighed at birth and weekly from 21 to 63 d of age, when wither height also was measured. Calves were vaccinated with 0.5 mg of ovalbumin on study d ?28 and ?7. Blood samples were collected on d ?28, ?25, ?21, ?11, 0, 3, 7, and 14. Polymorphonuclear leukocytes were isolated and challenged ex vivo with Escherichia coli to determine phagocytosis and oxidative burst capacity. Additionally, expression of cluster of differentiation (CD)62L and CD18 by granulocyte, lymphocyte, and CD14+ monocyte were determined. Blood samples were also used to determine hematological parameters and concentrations of growth hormone, insulin-like growth factor-1, insulin, glucose, fatty acids, β-hydroxybutyrate, haptoglobin, and anti-ovalbumin IgG. Calves treated with rbST had greater concentrations of growth hormone and insulin-like growth factor-1 from d ?25 to 14 than control calves, whereas insulin, fatty acid, and β-hydroxybutyrate concentrations did not differ. On d ?11, glucose concentration was greater for rbST-treated calves. Treatment did not affect polymorphonuclear lymphocyte phagocytosis and oxidative burst, but intensity of expression of CD62L and CD18 by granulocytes tended to be increased by rbST treatment. Treatment did not affect the concentration of anti-ovalbumin IgG in serum. Haptoglobin concentration was reduced in rbST treated calves on d 3 and we noted a tendency for hematocrit to be lower in rbST-treated calves. Treatment did not affect body weight, wither height, and average daily gain, despite the fact that rbST-treated calves had lower daily milk replacer intake. The relatively minor improvements in immune responses resulting from rbST treatment of weaning calves may not be sufficient to reduce the incidence of infectious diseases.     

Serum immunoglobulin profiles of dairy cows chronically treated with recombinant bovine somatotropin

The objective of this study was to determine the effects of exogenous somatotropin on blood profiles of the major bovine Ig isotypes. Holsteins were treated with either 0, 10.3, or 20.6 mg recombinant bST/d. Subcutaneous injections were started between wk 4 and 5 of lactation and continued for 266 d. Blood samples were collected by coccygeal venipuncture throughout lactation for serum IgG, G1, G2, A, and M concentration determination. Cows treated with 10.3 mg of bST/d exhibited modest increases in mean blood concentrations of IgG (12.4%) and IgG2 (18.4%) relative to the other groups of cows. In addition, treated cows had 10.1% higher average concentration of IgA than controls. Somatotropin did not influence average lactational concentrations of IgG1 or IgM, although the group receiving 10.3 mg/d had higher late lactation concentrations of IgG1 than did the other two groups. However, treatment mean isotype concentrations were always within normal ranges, except for IgG2 from the 10.3 mg/d group, which were higher. The practical significance of elevated serum Ig concentrations observed in the present study is not known. However, the present data do show that bST administered at doses that increased milk yield had no apparent detrimental effect on humoral immunity as measured by blood concentrations of Ig.     

Treatment of dairy cows with recombinant bovine somatotropin: genetic and phenotypic aspects

Thirty-four multiparous and primiparous Holstein cows were utilized to examine the association between the response to long-term administration of recombinant bovine somatotropin and the cow's phenotypic and genetic production potential. Cows representing a range of phenotypic and genetic production potentials were assigned to one of four treatment groups: 0, 12.5, 25.0, or 50.0 mg recombinant bovine somatotropin daily. They were injected daily for 266 d beginning on d 24 to 35 postpartum. Pretreatment milk and fat yields were used to predict daily yields over the lactation and allowed treatment groups to serve as their own controls. Actual minus predicted yield estimated the response to treatment for milk, fat, and FCM for each cow. Milk composition (fat, protein, and lactose percentage) was not significantly affected by treatment. Response in yield for milk, fat, and FCM was significant during the treatment period (266 d). Milk yield increased by 18.5, 19.9, and 21.4%; fat yield increased by 13.4, 20.3, and 18.1%; and FCM increased by 16.3%, 19.7%, and 21.1% after receipt of 12.5, 25.0 and 50.0 mg recombinant bovine somatotropin, respectively. Differences in response were not significant. The dramatic effect recombinant bovine somatotropin has on production requires that alternative approaches be adopted in the future for accurate genetic evaluation of sires and dams if somatotropin is discriminantly used in the national herd.     

Overall efficacy of chronically administered recombinant bovine somatotropin to lactating dairy cows

Recombinant bST at daily dosages of 0, 10.3, 20.6, and 41.2 mg/d were injected for 266 d into 8, 10, 9, and 9 Holstein cows, respectively. Treatment effects of recombinant bST were assessed for milk production traits, BW, blood components, and health and reproductive variables. Data reported compare controls to all bST-treated cows. There was an average increase of 18% in 3.5% FCM for bST versus control cows. This increase resulted in enhanced feed efficiency for bST cows, as their DM intakes were not elevated above those of the control cows. Recovery of BW was similar between control and bST groups. Milk composition was unaffected except for a slight decrease in protein percentage during the first 9 wk of treatment, and an elevated SCC between wk 19 and 28. Blood parameters were not different between control and bST cows, except for hematocrit, which decreased with bST treatment. The only health and reproductive parameters affected by bST were mastitis and days open, which were increased in the highest dosage groups.     

Effects of treatment of periparturient dairy cows with recombinant bovine somatotropin on health and productive and reproductive parameters

The objectives of the current experiment were to evaluate the effects of treating periparturient dairy cows with recombinant bovine somatotropin (rbST) on incidence of postpartum diseases and performance. Holstein (HO) and Jersey (JS) cows from 2 herds were enrolled in the experiment at 253 ± 3 d of gestation and assigned to the control (n = 432) and rbST125 (n = 437) treatments. Cows in the rbST125 treatment received 125 mg of rbST, weekly, from ?21 to 21 d relative to calving. Blood sampled weekly, from ?21 to 21 d relative to calving, from a subsample of cows was used to determine the concentrations of growth hormone (GH, HO = 106) and insulin-like growth factor 1 (IGF-1, HO = 147 and JS = 49). Cows were scored for body condition (BCS) at enrollment and at 1 ± 3, 30 ± 3, and 60 ± 3 d in milk (DIM). Cows were milked thrice daily and energy-corrected milk (ECM) yield was recorded for the first 30 DIM. Treatment of cows with rbST resulted in greater concentrations of GH during the prepartum (log₁₀ back-transformed concentrations of GH: HO-control = 7.83 and HO-rbST125 = 10.36 ng/mL) and postpartum (log₁₀ back-transformed concentrations of GH: HO-control = 10.45 and HO-rbST125 = 18.47 ng/mL) periods. Similarly, IGF-1 concentrations were higher during the prepartum (HO-control = 115.1 ± 4.9, HO-rbST125 = 137.7 ± 4.7, JS-control = 120.2 ± 8.3, JS-rbST125 = 167.1 ± 8.1 ng/mL) and postpartum (HO-control = 61.3 ± 4.0, HO-rbST125 = 75.2 ± 3.8, JS-control = 35.5 ± 6.9, JS-rbST125 = 54.6 ± 6.9 ng/mL) periods for rbST-treated cows. During the prepartum period, BCS was not affected by treatment, but during the postpartum period, BCS was reduced for rbST-treated cows (HO-control = 3.00 ± 0.03, HO-rbST125 = 2.90 ± 0.03, JS-control = 2.64 ± 0.02, JS-rbST125 = 2.61 ± 0.02). Cows from the rbST125 treatment tended to have lower incidence of retained fetal membranes (HO-control = 14.3, HO-rbST125 = 6.1, JS-control = 1.5, JS-rbST125 = 1.2%) and had reduced incidence of metritis (HO-control = 26.2, HO-rbST125 = 16.6, JS-control = 19.9, JS-rbST125 = 13.3%) compared with control cows. Ketosis incidence tended to be higher for rbST125 cows (HO-control = 9.4, HO-rbST125 = 11.3, JS-control = 8.5, JS-rbST125 = 13.4%) compared with control cows. The interaction between treatment and herd tended to affect yield of ECM during the first 30 DIM because HO cows treated with rbST during the periparturient period had greater yield than control HO cows (HO-control = 35.5 ± 1.0 vs. HO-rbST125 = 39.4 ± 1.0 kg/d), but treatment with rbST did not affect yield of ECM of JS cows (JS-control = 26.7 ± 0.6 vs. JS-rbST125 = 27.8 ± 0.6 kg/d). Treatment of periparturient dairy cows with 125 mg of rbST decreased the incidence of uterine disorders in HO and JS cows and increased yield of ECM during the first 30 DIM among HO cows, despite slightly increasing the incidence of ketosis.     

Responses by lactating cows in commercial dairy herds to recombinant bovine somatotropin

Cows (890) in 15 US herds were assigned randomly in equal numbers to control or bST injections (500 mg in a prolonged-release form every 14 d for 12 wk) within three stages of lactation (57 to 100, 101 to 140, and 141 to 189 d postpartum) and two parity groups (primiparous and multiparous). Yield and milk composition were monitored 1 d/wk for 16 wk including 2 wk pretreatment and 2 wk posttreatment. Increases in milk and FCM due to bST injections were less at 57 to 100 d than at 101 to 189 d postpartum (milk 3.6 vs. 5.5; FCM 3.9 vs. 6.1 kg/d per cow), and increases in milk and FCM were more for multiparous than for primiparous cows (milk 5.5 vs. 4.2; FCM 6.0 vs. 4.7 kg/d cow). Temporarily, concentration of milk fat increased and protein decreased; later, concentrations for control and injected cows were similar. Postinjection milk fat concentration decreased, but milk protein concentration increased temporarily. The net increase in milk (and FCM) varied significantly among herds from 2.9 to 7.6 kg/d per cow (mean, 4.9 kg). Responses in FCM were similar over a wide range of pretreatment yields. A great variety of feed ingredients were fed as total mixed rations, and nutrient concentrations varied greatly. The SCC were similar before, during, and after treatment, but increase in FCM of injected cows exhibited a negative correlation with pretreatment SCC. Changes in body condition score of sometribove-injected cows varied among herds (.25 to -.45) and averaged -.02 compared with .07 for controls. There was no pattern in incidence of mastitis during sometribove injections.     

Effects of insulin,recombinant bovine somatotropin,and their interaction on insulin-like growth factor-I secretion and milk protein production in dairy cows

This trial was designed to test the effects of insulin, recombinant bovine somatotropin (rbST), and their interaction on milk protein and selected blood parameters in dairy cows. Eight Holstein cows (86 +/- 10 d in milk) were divided in two groups and used in two replicates of a Latin square design with four animals, four periods, and four treatments: 1) intravenous infusion of saline, 2) infusion of saline and subcutaneous administration of 40 mg of rbST per day, 3) intravenous infusion of 12 mg of insulin per day coupled with glucose infusion, and 4) rbST administration combined with insulin and glucose infusion. The glucose infusion rate was adjusted to maintain euglycemia. Each experimental period lasted 14 d: treatments were administered during the first 6 d, and no treatment was administered during the following 8-d resting phase. The average daily amount of glucose infusion needed to avoid hypoglycemia was 2.8 kg/cow when only insulin was infused as opposed to 2.2 kg/cow when both insulin and rbST were administered, indicating that either rbST causes a peripheral resistance to insulin or rbST increased liver gluconeogenesis or both. Data from the last 3 d of infusion were analyzed by using the SAS system for mixed models. Percent protein of milk tended to be lower (2.84 vs. 2.79%) and milk urea content was lower (16.6 vs. 14.8 mg/dl) during rbST administration, regardless of insulin infusion. Insulin infusion increased percent protein (2.78 vs. 2.85%) and percent casein (2.36 vs. 2.46%) and decreased milk urea content (17.1 vs. 14.3 mg/dl) regardless of rbST administration. For milk yield, protein yield, casein yield, lactose percent, and lactose yield, there were significant interactions between insulin and rbST administration. For example, casein yield averaged 1.17, 1.12, 1.20, and 1.28 kg/d for saline, insulin, rbST, and insulin combined with rbST, respectively. Similarly, there was a significant interaction between insulin and rbST on IGF-I levels, which were 122.5, 181.3, 342.3, and 492.2 ng/ml for saline, insulin, rbST, and insulin combined with rbST, respectively. In conclusion, these results clearly demonstrated that insulin interacts with bST in early lactation to improve milk protein synthesis and yield in dairy cows. These effects are probably mediated through a combination of bST nutrient mobilization, bST-induced gluconeogenesis, bST-induced insulin peripheral resistance, and bST/insulin synergism on insulin-like growth factor-I secretion and on mammary epithelial tissue.     

Effect of prepartum administration of recombinant bovine somatotropin on health and performance of lactating dairy cows

A double-blind, randomized clinical trial was conducted in 5 commercial dairy herds in southern Ontario with 1,362 cows enrolled to evaluate the effect of prepartum administration of recombinant bovine somatotropin (rbST) on health and performance. Cows were randomly assigned to receive either 325 mg of sometribove zinc suspension (n = 680) or a placebo injection (n = 682; control) subcutaneously every 14 d until calving. Treatments started 28 to 22 d before expected calving, with a maximum of 3 treatments per cow. Serum samples taken at the time of enrollment, 1 wk before calving, and weekly for 3 wk after calving were analyzed for nonesterified fatty acids (NEFA), β-hydroxybutyrate (BHBA), glucose, aspartate aminotransferase, calcium, and haptoglobin. Diseases were recorded by farm staff. Incidences of clinical ketosis, clinical mastitis, displaced abomasum, metritis, retained placenta, milk fever, and lameness were similar between groups. Body condition score was lower for treated than for control cows at 3 wk after calving (3.13 and 3.17, respectively). Serum NEFA tended to be higher for treated than for control cows by 0.01 mmol/L. Overall BHBA was not different between groups, but BHBA for treated cows was higher in wk 1 after calving (750 and 698 μmol/L, respectively) and tended to be higher in wk 2 after calving (779 and 735 μmol/L, respectively). Incidence of hyperketonemia was similar between groups. Treated cows had higher serum glucose compared with control cows (2.8 and 2.7 mmol/L, respectively). We detected no differences in serum aspartate aminotransferase, calcium, or haptoglobin between groups. Milk yield was recorded daily for each cow for 63 d, and did not differ between groups (37.1 ± 0.5 kg and 36.7 ± 0.5 kg, respectively) but we detected a tendency for treated cows to produce 0.8 kg/d more milk than control cows in wk 1 after calving. We observed no difference between groups in the time from calving to first insemination or the probability of pregnancy at the first insemination. Groups did not differ in the proportion of anovular cows at 53 ± 3 d in milk based on serum progesterone measured from a subset of cows (38.0 and 34.3%, respectively, for treated and control groups). We found no difference between groups in dry matter intake from 21 d before calving to 63 d after calving in a subset of cows (17.4 ± 0.4 and 17.5 ± 0.4 kg/d, respectively). Based on results of the current study, biweekly (every 14 d) administration of rbST before calving to prevent disease and enhance performance is not recommended.     

Effects of grain processing and bovine somatotropin on metabolism and ovarian activity of dairy cows during early lactation

This study compared the effects of exogenous bovine somatotropin (bST) on the metabolism and ovarian activity of cows fed diets differing in ruminally degradable starch. Twenty-four multiparous and eight primiparous Holstein cows in early lactation were divided into four groups and fed diets containing 39% grain as steam-flaked sorghum or steam-rolled corn with or without bST for 90 d in a 2 x 2 factorial design. Flaked sorghum improved energy status of cows during early lactation, tending to increase plasma glucose and insulin. Administration of bST decreased plasma urea nitrogen and increased nonesterified fatty acids (NEFA). Plasma levels of beta-hydroxybutyrate (BHBA) and hepatic concentrations of triglycerides were not altered by treatments. Temporal changes in plasma glucose, urea nitrogen, NEFA, and BHBA were detected in a quadratic manner and insulin increased linearly with time, but treatments did not affect postpartum changes in these metabolites. There were greater decreases in body weight and net energy balance in cows on bST during the first 7 wk of treatment. Cows receiving bST took longer to reach the nadir of negative energy balance, and bST tended to delay the period to reach a positive energy balance. Follicular populations and incidence of cystic ovaries were not affected by treatments, but cows receiving bST had fewer double ovulations. Flaked sorghum increased plasma progesterone during the early luteal phase of the first two postpartum estrous cycles. Feeding more ruminally degradable starch improved the energy status and luteal activity of cows in early lactation.     

Effects of presynchronization and bovine somatotropin on pregnancy rates to a timed artificial insemination protocol in lactating dairy cows

The objective was to examine the effects of presynchronization and bovine somatotropin (bST) on pregnancy rates to a timed artificial insemination protocol in lactating dairy cows. Lactating Holstein cows (n = 543) were assigned randomly in a 2 x 3 factorial experiment in which cows received a presynchronization treatment or not, and were treated with bST (500 mg) at 63 +/- 3, 73 +/- 3, or 147 +/- 3 d postpartum. The latter group was used as a control. Presynchronization treatment consisted of two injections of PGF2alpha (25 mg) given 14 d apart, with the second injection of PGF2alpha being administered 12 d before initiation of the timed artificial insemination protocol. All cows received GnRH (100 microg) at 63 +/- 3 d postpartum, an injection of PGF2alpha (40 mg) 7 d later, a GnRH injection at 48 h after PGF2alpha and were inseminated 16 to 20 h later. Cows were resynchronized if determined to be nonpregnant at ultrasonography at 32 d after insemination with a GnRH injection (100 microg), an injection of PGF2alpha (40 mg) 7 d later, and a GnRH injection at 48 h after PGF2alpha and were inseminated 16 to 20 h later. Cows were examined for pregnancy at 32 d and reexamined at 74 d after insemination. No differences in pregnancy rates were observed between cows receiving bST treatment at 63 +/- 3 d postpartum or at 73 +/- 3 d postpartum. An interaction between presynchronization and bST treatment indicated that pregnancy rates were increased for cows treated with bST when cows were presynchronized. When anestrous cows were excluded from the analyses, both an effect of bST and of presynchronization were observed, indicating that bST increased pregnancy rates regardless of presynchronization treatment and that presynchronization also increased pregnancy rates independently of bST treatment. Presynchronization and bST treatment may be used to increase first-service pregnancy rates to a timed artificial insemination protocol.     

Contact sensitivity and systemic antibody responses in dairy cows treated with recombinant bovine somatotropin.

Effects of exogenous bST on humoral and cell-mediated immune responses in lactating dairy cows were determined. The systemic antibody response to human erythrocytes and the cutaneous sensitivity response induced by dinitrochlorobenzene were the immune responses investigated. Cows were treated with either 0, 10.3, or 20.6 mg of bST/d for 266 d starting between wk 4 and 5 of lactation. Systemic immunizations and contact sensitivity were initiated during midlactation, 22 wk after bST treatments began. Hemagglutinating antibody titers and areas under the response profiles were not statistically different for bST-treated versus control cows. The cutaneous sensitivity response was similarly not affected by bST administration. Present antibody titer results agreed with our previous observations that bST did not affect serum IgM concentrations, but the cutaneous sensitivity results were in contrast with our finding of augmented proliferative responsiveness of mitogen-stimulated peripheral blood lymphocytes in bST-treated versus control cows. It is possible that exogenous bST affects some immune processes and lymphocyte subsets and not others. Further research is required to determine the practical significance of the variable immunomodulation elicited by exogenous bST.     

Response to recombinant bovine somatotropin in dairy cows with different genetic merit for milk production

Thirty-nine multiparous cows obtained from two genetic lines were utilized to determine the effect of genetic merit on lactation response to long-term administration of recombinant bST. Cow index ranged from -70 to 456 (mean = 183) and -494 to -88 (mean = -288) kg milk for high and low genetic groups, respectively. Cows were blocked by calving date and randomly assigned to treatment within genetic group. Treatments were 0, 10.3, 20.6, and 30.9 mg somatotropin injected daily from wk 14 through 44 postpartum. Cows were fed one of two total mixed rations. Diet 1 (NE1 = 1.65 Mcal/kg, CP = 18%, and ADF = 22%) was fed from start of lactation to at least 4 wk after initiation of treatment. Cows were switched to diet 2 (NE1 = 1.56 Mcal/kg, CP = 16%, and ADF = 27%) when milk output fell below 25 kg/d. Forty-four week lactation yields were 9800 and 9447 kg milk; 364 and 354 kg fat; and 322 and 309 kg protein for high and low genetic groups, respectively. Milk, milk fat, or protein yield due to somatotropin did not differ between genetic groups. Increasing dosage of bST increased milk, 4% FCM, fat, and protein yields in a linear fashion. Percentages of fat and protein of milk were similar for all treatment groups. Body weight changes were not significantly different among treatments, but condition score changes decreased linearly with increasing dose of bST. Long-term treatment with recombinant bST had no apparent effect on incidence of health problems or reproduction.     

Responses of high-producing dairy cows to long-term treatment with pituitary somatotropin and recombinant somatotropin

Thirty Holstein cows capable of high milk production were utilized to examine the effects of long-term administration of bovine somatotropin on lactational performance. Treatments were 0 (control), 13.5, 27, and 40.5 mg/day of recombinantly-derived bovine somatotropin and 27 mg/day of pituitary-derived bovine somatotropin. Hormone was injected intramuscularly, once daily beginning at 84 +/- 10 days postpartum and continuing for 188 days. Cows were fed ad libitum a total mixed diet throughout the lactation. Recombinant somatotropin treatments increased average fat-corrected milk yield in a dose-dependent fashion from 23 to 41% over the control production (27.9 kg/day. Pituitary somatotropin (27 mg/day) increased milk production by 16%. Milk lactose, protein, and fat composition was similar for all treatments. Control cows were in positive energy balance throughout the treatment period (4.7 Mcal net energy/day. Initially, the large increase in milk yield with somatotropin treatment caused cows to decrease in energy balance. However, voluntary intake gradually increased, and by week 10 of treatment all somatotropin treatment groups were in positive energy balance. Thus, the gain in body weight over the treatment period was similar for all groups, ranging from 17 to 22%. Gross lactational efficiency (milk per unit of net energy intake) was improved by exogenous somatotropin whether calculated as observed, corrected for body weight changes, or using the theoretical energy requirements for maintenance and milk production. Results are consistent with bovine somatotropin as a homeorhetic control that coordinates an array of physiological processes so that nutrients are partitioned for milk synthesis.     

Dose response to recombinant bovine somatotropin from weeks 15 to 44 postpartum in lactating dairy cows

Forty Holstein cows were used in an experiment to determine the response of cows to daily subcutaneous injections of 0, 10.3, 20.6, and 30.9 mg of recombinant bST. Injections began between 98 and 104 d postpartum and continued for 29 wk, up to 70 d prepartum, or a maximum of 400 d postpartum. Increasing recombinant bST increased milk yield and 3.5% FCM yield in a linear fashion and by 5.2 and 5.7 kg/d, respectively. Milk composition was not changed, and DM intake as a percentage of BW increased from 3.39 to 3.80% with increasing (30.9 mg/d) bST. Feed efficiency (3.5% FCM/DM intake) was increased from 1.35 to 1.64 with increasing dose, suggesting improved efficiency of use of DM intake, primarily by dilution of maintenance. Increasing bST reduced BW gain linearly from .46 kg/d for the control to .22 kg/d for the 30.9 mg/d bST. Calf birth weight, weight of cows at calving, and incidence of metabolic diseases during subsequent calving were not affected by bST. Somatotropin treatment resulted in somewhat smaller increased in milk yield than that reported in previous studies. Long-term health effects and effects on reproduction could not be determined from the relatively few cows used in this study.     

Effect of recombinant bovine somatotropin and a shortened or no dry period on the performance of lactating dairy cows

The objective of this study was to determine the effects of altering dry period length in multiparous dairy cows (n = 341) on milk production for a full lactation (294 d). The study used 3 commercial herds in the western United States. Cows producing greater than 8,400 kg of mature-equivalent milk were assigned to treatments 60 d before their due dates. The 4 treatments were 1) 60-d dry period, label use of recombinant bovine somatotropin (rbST; 60d-L); 2) 32-d dry period, label use of rbST (32d-L); 3) 0-d dry period, label use of rbST (0d-L); and 4) 0-d dry period, continuous use of rbST (0d-C). Cows with shortened dry periods produced 625, 1,000, and 1,042 kg of milk during the prepartum period for treatments 2 to 4, respectively. During the postpartum period, cows on the 32d-L treatment produced similar amounts of milk compared with the 60d-L treatment (11,490 vs. 11,968 kg, respectively). However, cows on the 0d-L (10,316 kg) and 0d-C (10,195 kg) treatments produced significantly lower amounts of milk during the postpartum period compared with the 60d-L treatment. Total milk production from the prepartum and postpartum periods was not altered significantly and was 11,974, 12,112, 11,310, and 11,230 kg for treatments 1 to 4, respectively. The concentrations of β-hydroxybutyrate and nonesterified fatty acids in serum after calving were decreased for cows on the 32d-L, 0d-L, and 0d-C treatments compared with cows on the 60d-L treatment, which may indicate improved metabolic status.     

Economics of using bovine somatotropin in dairy cows and potential impact on the US dairy industry

Budgets with a microcomputer spreadsheet were developed to evaluate the economics of bovine somatotropin use and to estimate the impact on US dairy cow numbers. Income over feed and variable costs increased with somatotropin use and low feed prices. With high feed prices, income responses were less favorable, and when combined with low milk prices, somatotropin use resulted in less income than from control cows. Price of somatotropin did not have a major effect on production costs. The number of cows needed to meet US milk requirements is primarily influenced by per capita consumption and production per cow. With continuing yearly increases in per capita consumption of 2 kg of milk equivalent and cow milk yields of 114 kg, the number of milk cows needed through 1992 remains at the 1987 figure of approximately 10.3 million. In the scenario of a 15% increase in milk yield due to somatotropin, 20% of cows receiving the hormone, and cows receiving the hormone being 10% above the national average of all cows; the number needed in 1992 is 9.77 million, or a drop of 5.4% from 1987. Somatotropin use will have a less drastic effect on cow numbers than originally predicted.